- Home
- ROIV vs ERIE Comparison
ROIV vs ERIE Comparison
Compare ROIV & ERIE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | ERIE |
|---|---|---|
| Founded | 2014 | 1925 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 15.0B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ERIE |
|---|---|---|
| Price | $22.78 | $276.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $24.31 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 139.2K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 2.12% |
| EPS Growth | N/A | ★ 15.90 |
| EPS | N/A | ★ 12.39 |
| Revenue | $20,329,000.00 | ★ $4,040,325,000.00 |
| Revenue This Year | N/A | $9.98 |
| Revenue Next Year | $741.42 | $5.75 |
| P/E Ratio | ★ N/A | $22.26 |
| Revenue Growth | N/A | ★ 9.53 |
| 52 Week Low | $8.73 | $273.59 |
| 52 Week High | $23.91 | $456.93 |
Technical Indicators
Market Signals| Indicator | ROIV | ERIE |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 41.87 |
| Support Level | $22.50 | $275.00 |
| Resistance Level | $23.20 | $290.08 |
| Average True Range (ATR) | 0.75 | 7.73 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 63.73 | 5.94 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ERIE Erie Indemnity Company
Erie Indemnity Co mainly performs services on behalf of the Erie Insurance Exchange relating to sales, underwriting, and issuance of policies. Erie Indemnity's results are tied to the performance of the Insurance Exchange, which principally provides automobile and homeowners insurance for individuals, along with multiperil, workers' compensation, and commercial automobile insurance for its commercial clients. The company operates exclusively in the United States.